普罗塞普生物机器人获得FDA批准,用于使用AI驱动的HYDROS机器人手术系统治疗癌症. Procept BioRobotics receives FDA clearance for AI-powered HYDROS robotic surgery system for cancer treatment.

Procept BioRobotics Corp.的下一代HYDROS机器人手术系统获得了FDA的批准，该系统使用Aquablation疗法进行癌症治疗。 Procept BioRobotics Corp. received FDA clearance for its next-generation HYDROS robotic surgery system, which uses Aquablation therapy for cancer treatment. AI-动力平台提高了效率,增强了外科医生和工作人员的经验,并提供了更准确和一致的治疗计划。 The AI-powered platform improves efficiency, enhances surgeon and staff experience, and delivers more accurate and consistent treatment plans. 该公司计划在美国安装400多个机器人系统之后,在Q4 2024中从遗留系统过渡到新系统。 The company plans to transition from legacy to new systems in Q4 2024 after installing over 400 robotic systems in the US.